Compare ICL & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICL | ROIV |
|---|---|---|
| Founded | 1968 | 2014 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 14.1B |
| IPO Year | N/A | N/A |
| Metric | ICL | ROIV |
|---|---|---|
| Price | $5.62 | $20.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $6.23 | ★ $21.19 |
| AVG Volume (30 Days) | 914.1K | ★ 7.6M |
| Earning Date | 11-12-2025 | 11-10-2025 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $7,053,000,000.00 | $20,329,000.00 |
| Revenue This Year | $6.36 | N/A |
| Revenue Next Year | $5.29 | $376.94 |
| P/E Ratio | $19.48 | ★ N/A |
| Revenue Growth | ★ 1.77 | N/A |
| 52 Week Low | $4.56 | $8.73 |
| 52 Week High | $7.35 | $21.35 |
| Indicator | ICL | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 44.08 | 55.77 |
| Support Level | $5.27 | $19.99 |
| Resistance Level | $5.56 | $20.99 |
| Average True Range (ATR) | 0.11 | 0.60 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 95.89 | 16.42 |
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates maximum revenue from Brazil followed by, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.